Docket Room.
HR 1843·Federal·house

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

In CommitteeFiled Mar 5, 2025
Sponsor: Rep. Dunn, Neal P. [R-FL-2] (R)
Latest Action

Referred to the House Committee on Energy and Commerce.

Mar 5, 2025

Email me when HR 1843 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track HR 1843. By continuing you agree to the Terms and Privacy Policy.

Legislative status

  1. Introduced
  2. In Committee
  3. Reported by Committee
  4. Floor Vote Scheduled
  5. Passed One Chamber
  6. Passed Both Chambers
  7. Sent to Executive
  8. Signed into Law

Summary

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about HR 1843

3 free questions a day, no account

Hearings

History

  1. Referred to the House Committee on Energy and Commerce.
  2. Introduced in House

Sponsors

  • Rep. Dunn, Neal P. [R-FL-2] (R) · sponsor
  • Rep. Mullin, Kevin [D-CA-15] (D)

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when HR 1843 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track HR 1843 free

Or ask your AI assistant about HR 1843 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice